Galmed Pharmaceuticals Ltd. (GLMD) Earns “Buy” Rating from Maxim Group

Maxim Group reaffirmed their buy rating on shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in a research report released on Thursday. Maxim Group currently has a $14.00 target price on the biopharmaceutical company’s stock.

“Galmed reported 3Q17, spending just $2.8M and closing the period with $9M in cash. Management was clear that with their efforts to preserve cash, they have runway through 2018 and through catalysts; data from both ARRIVE and ARREST studies.”,” the firm’s analyst commented.

Several other equities research analysts have also recently issued reports on the stock. HC Wainwright restated a buy rating and set a $18.00 price objective on shares of Galmed Pharmaceuticals in a research report on Friday, October 27th. Zacks Investment Research cut shares of Galmed Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, October 11th. Finally, Seaport Global Securities reiterated a buy rating and set a $19.00 price target on shares of Galmed Pharmaceuticals in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $14.75.

Galmed Pharmaceuticals (GLMD) traded down $0.07 during trading on Thursday, reaching $6.78. 19,700 shares of the company traded hands, compared to its average volume of 35,319. Galmed Pharmaceuticals has a 52-week low of $3.04 and a 52-week high of $9.59.

WARNING: “Galmed Pharmaceuticals Ltd. (GLMD) Earns “Buy” Rating from Maxim Group” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. GRT Capital Partners L.L.C. purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 18,314 shares of the biopharmaceutical company’s stock, valued at approximately $114,000. GRT Capital Partners L.L.C. owned about 0.15% of Galmed Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply